Advances in Targeted Therapies and Pharmacogenomics of Leukemia
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 41
Special Issue Editor
Interests: RAC; RAS; targeted therapy; leukemia; drug mechanism of action; mechanisms of resistance; pharmacogenetics
Special Issue Information
Dear Colleagues,
Leukemia is a malignancy of the blood and bone marrow, characterized by the uncontrolled proliferation of abnormal white blood cells. It ranks among the most prevalent cancers in children and remains a leading cause of cancer-related mortality in the elderly. Over the past three decades, global incidence and mortality rates have gradually declined, primarily due to advancements in diagnostic techniques and therapeutic interventions. Nonetheless, disparities in outcome persist across different regions and demographic groups.
Treatment strategies are tailored to the specific leukemia subtype and individual patient characteristics and commonly include chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. Innovative approaches such as CAR-T and CAR-NK cell therapies, along with novel targeted agents, are improving outcomes and survival rates. However, despite encouraging initial responses, disease recurrence remains a significant clinical challenge.
We are pleased to invite you to contribute your valuable work to this Special Issue titled “Advances in Targeted Therapies and Pharmacogenomics of Leukemia”.
This Special Issue aims to collect papers focused on the recent advances in targeted therapies in leukemia, how they induce leukemic cell death, their effects on the genome/epigenome and on the tumor microenvironment, and how genetic variations influence patients’ response.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Mechanisms of action and mechanisms of resistance to targeted therapies;
- Pharmacogenetics studies;
- Metabolomics studies;
- Combination therapies;
- Biomarkers for treatment success;
- Targeting invasive leukemia;
- Rare blood cancers.
I look forward to receiving your contributions.
Dr. Nicolas Nassar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- blood cancer
- targeted therapy
- immunotherapy
- primary and secondary resistance
- pharmacogenetics
- combination therapy
- tumor microenvironment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
